EE200100007A - Kinoliini derivaadid, nende kasutamine ravimina, neid sisaldavad farmatseutilised kompositsioonid ning ühendite ja farmatseutiliste kompositsioonide kasutamine patoloogilisest põletikust ja autoimmuunsusest tingitud haiguste ravis - Google Patents
Kinoliini derivaadid, nende kasutamine ravimina, neid sisaldavad farmatseutilised kompositsioonid ning ühendite ja farmatseutiliste kompositsioonide kasutamine patoloogilisest põletikust ja autoimmuunsusest tingitud haiguste ravisInfo
- Publication number
- EE200100007A EE200100007A EEP200100007A EEP200100007A EE200100007A EE 200100007 A EE200100007 A EE 200100007A EE P200100007 A EEP200100007 A EE P200100007A EE P200100007 A EEP200100007 A EE P200100007A EE 200100007 A EE200100007 A EE 200100007A
- Authority
- EE
- Estonia
- Prior art keywords
- pharmaceutical compositions
- autoimmunity
- medicaments
- compounds
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9802550A SE9802550D0 (sv) | 1998-07-15 | 1998-07-15 | Quinoline derivatives |
PCT/SE1999/001271 WO2000003992A1 (en) | 1998-07-15 | 1999-07-14 | Quinoline derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
EE200100007A true EE200100007A (et) | 2002-06-17 |
EE04276B1 EE04276B1 (et) | 2004-04-15 |
Family
ID=20412094
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EEP200100007A EE04276B1 (et) | 1998-07-15 | 1999-07-14 | Kinoliini derivaadid, nende valmistamine ja kasutamine ravimina ning neid sisaldavad farmatseutilised kompositsioonid |
Country Status (31)
Country | Link |
---|---|
EP (1) | EP1097139B1 (et) |
JP (1) | JP4082865B2 (et) |
KR (1) | KR100551611B1 (et) |
CN (1) | CN1114597C (et) |
AP (1) | AP1425A (et) |
AT (1) | ATE229005T1 (et) |
AU (1) | AU745915B2 (et) |
BR (1) | BR9912104B1 (et) |
CA (1) | CA2334718C (et) |
DE (1) | DE69904333T2 (et) |
DK (1) | DK1097139T3 (et) |
EE (1) | EE04276B1 (et) |
ES (1) | ES2187176T3 (et) |
HK (1) | HK1035716A1 (et) |
HR (1) | HRP20010038A2 (et) |
HU (1) | HUP0103634A3 (et) |
ID (1) | ID27547A (et) |
IL (1) | IL140009A0 (et) |
IS (1) | IS2187B (et) |
NO (1) | NO317545B1 (et) |
NZ (1) | NZ508924A (et) |
OA (1) | OA11580A (et) |
PL (1) | PL200147B1 (et) |
PT (1) | PT1097139E (et) |
RU (1) | RU2213734C2 (et) |
SE (1) | SE9802550D0 (et) |
TR (1) | TR200100086T2 (et) |
UA (1) | UA70944C2 (et) |
WO (1) | WO2000003992A1 (et) |
YU (1) | YU1401A (et) |
ZA (1) | ZA200007493B (et) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0002320D0 (sv) * | 1999-10-25 | 2000-06-21 | Active Biotech Ab | Malignant tumors |
CZ20031028A3 (cs) | 2000-10-12 | 2003-08-13 | Merck & Co., Inc. | Aza- a polyazanaftalenylkarboxamidy |
AU1532802A (en) | 2000-10-12 | 2002-04-22 | Merck & Co Inc | Aza- and polyaza-naphthalenyl-carboxamides useful as hiv integrase inhibitors |
AU2003218130A1 (en) | 2002-03-15 | 2003-09-29 | Merck And Co., Inc. | N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7- carboxamides useful as hiv integrase inhibitors |
SE0201778D0 (sv) * | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
US8314124B2 (en) | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
SE0401578D0 (sv) * | 2004-06-18 | 2004-06-18 | Active Biotech Ab | Novel compounds |
NZ592897A (en) | 2005-10-19 | 2012-12-21 | Teva Pharma | Crystals of laquinimod sodium, and process for the manufacture thereof |
EP2035001B1 (en) | 2006-06-12 | 2011-11-09 | Teva Pharmaceutical Industries Limited | Stable laquinimod preparations |
SI2234485T1 (sl) | 2007-12-20 | 2014-03-31 | Teva Pharmaceutical Industries Ltd. | Stabilni lakvinimodni pripravki |
NZ591315A (en) | 2008-09-03 | 2012-08-31 | Teva Pharma | 2-oxo-1,2-dihydro-quinoline modulators of immune function |
CN102480960A (zh) | 2009-07-30 | 2012-05-30 | 泰华制药工业有限公司 | 利用拉喹莫德治疗克隆氏病 |
AU2010282948C1 (en) | 2009-08-10 | 2017-03-02 | Active Biotech, Ab | Treatment of BDNF-related disorders using laquinimod |
BR112012021905A2 (pt) | 2010-03-03 | 2015-09-29 | Teva Pharma | tratamento de nefrite lúpica usando laquinimod |
EP2542079B1 (en) | 2010-03-03 | 2014-05-21 | Teva Pharmaceutical Industries Ltd. | Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate |
AR082150A1 (es) | 2010-07-09 | 2012-11-14 | Teva Pharma | N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolin-3-carboxamida deuterada, sales y usos de la misma, metodo de tratamiento, mezcla compuestos, composicion farmaceutica, proceso de preparacion, compuesto enriquecido con deuterio |
KR20130065728A (ko) | 2010-10-14 | 2013-06-19 | 임뮤나르 에이비 | Ahr 활성화제로서의 1,2-디히드로-4-히드록시-2-옥소-퀴놀린-3-카르복사닐리드 |
CN103974704A (zh) | 2011-10-12 | 2014-08-06 | 泰华制药工业有限公司 | 以拉喹莫德和芬戈莫德的组合治疗多发性硬化症 |
CN104093310A (zh) | 2012-02-03 | 2014-10-08 | 泰华制药工业有限公司 | 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途 |
KR20140138725A (ko) | 2012-02-16 | 2014-12-04 | 테바 파마슈티컬 인더스트리즈 리미티드 | N-에틸-n-페닐-1,2-디하이드로-4,5-디-하이드록시-1-메틸-2-옥소-3-퀴놀린카복사미드, 그의 제조 및 용도 |
TW201350467A (zh) | 2012-05-08 | 2013-12-16 | Teva Pharma | N-乙基-4-羥基-1-甲基-5-(甲基(2,3,4,5,6-五羥基己基)胺基)-2-側氧-n-苯基-1,2-二氫喹啉-3-甲醯胺 |
TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療gaba媒介之疾病之拉喹莫德(laquinimod) |
CA2890194A1 (en) | 2012-11-07 | 2014-05-15 | Teva Pharmaceutical Industries Ltd. | Amine salts of laquinimod |
WO2014153145A2 (en) | 2013-03-14 | 2014-09-25 | Teva Pharmaceutical Industries Ltd. | Crystals of laquinimod sodium and improved process for the manufacture thereof |
SG11201608674UA (en) | 2014-04-29 | 2016-11-29 | Teva Pharma | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE52670B1 (en) * | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
GB9108547D0 (en) * | 1991-04-22 | 1991-06-05 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
SE469368B (sv) * | 1991-10-09 | 1993-06-28 | Kabi Pharmacia Ab | Ny anvaendning av linomide foer tillverkning av laekemedel foer behandling av multiple sclerosis (ms) |
CN1063686A (zh) * | 1992-03-12 | 1992-08-19 | 华西医科大学药物研究所 | 用活性酯法合成维司力农 |
SE9201076L (sv) * | 1992-04-06 | 1993-10-07 | Shimon Slavin | Användningen av gamla läkemedel för behandling av diabetes |
JPH07224040A (ja) * | 1994-02-07 | 1995-08-22 | Fujisawa Pharmaceut Co Ltd | キノリン誘導体 |
GB9404378D0 (en) * | 1994-03-07 | 1994-04-20 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
SE9400809D0 (sv) * | 1994-03-10 | 1994-03-10 | Pharmacia Ab | New use of quinoline-3-carboxamide compounds |
SE9400810D0 (sv) * | 1994-03-10 | 1994-03-10 | Pharmacia Ab | New use of Quinoline-3-carboxamide compounds |
GB2290786A (en) * | 1994-06-30 | 1996-01-10 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
-
1998
- 1998-07-15 SE SE9802550A patent/SE9802550D0/xx unknown
-
1999
- 1999-07-14 OA OA1200100012A patent/OA11580A/en unknown
- 1999-07-14 NZ NZ508924A patent/NZ508924A/xx not_active IP Right Cessation
- 1999-07-14 EP EP99935261A patent/EP1097139B1/en not_active Expired - Lifetime
- 1999-07-14 AP APAP/P/2001/002040A patent/AP1425A/en active
- 1999-07-14 CA CA002334718A patent/CA2334718C/en not_active Expired - Fee Related
- 1999-07-14 IL IL14000999A patent/IL140009A0/xx not_active IP Right Cessation
- 1999-07-14 WO PCT/SE1999/001271 patent/WO2000003992A1/en active IP Right Grant
- 1999-07-14 AU AU50775/99A patent/AU745915B2/en not_active Ceased
- 1999-07-14 PT PT99935261T patent/PT1097139E/pt unknown
- 1999-07-14 HU HU0103634A patent/HUP0103634A3/hu unknown
- 1999-07-14 ID IDW20010360A patent/ID27547A/id unknown
- 1999-07-14 DK DK99935261T patent/DK1097139T3/da active
- 1999-07-14 JP JP2000560099A patent/JP4082865B2/ja not_active Expired - Fee Related
- 1999-07-14 CN CN99808597A patent/CN1114597C/zh not_active Expired - Fee Related
- 1999-07-14 EE EEP200100007A patent/EE04276B1/et not_active IP Right Cessation
- 1999-07-14 KR KR1020007014281A patent/KR100551611B1/ko not_active IP Right Cessation
- 1999-07-14 RU RU2001104344/04A patent/RU2213734C2/ru not_active IP Right Cessation
- 1999-07-14 YU YU1401A patent/YU1401A/sh unknown
- 1999-07-14 BR BRPI9912104-2A patent/BR9912104B1/pt not_active IP Right Cessation
- 1999-07-14 ES ES99935261T patent/ES2187176T3/es not_active Expired - Lifetime
- 1999-07-14 DE DE69904333T patent/DE69904333T2/de not_active Expired - Lifetime
- 1999-07-14 UA UA2000127137A patent/UA70944C2/uk unknown
- 1999-07-14 TR TR2001/00086T patent/TR200100086T2/xx unknown
- 1999-07-14 PL PL345389A patent/PL200147B1/pl unknown
- 1999-07-14 AT AT99935261T patent/ATE229005T1/de not_active IP Right Cessation
-
2000
- 2000-12-05 IS IS5753A patent/IS2187B/is unknown
- 2000-12-14 ZA ZA200007493A patent/ZA200007493B/en unknown
-
2001
- 2001-01-12 NO NO20010210A patent/NO317545B1/no unknown
- 2001-01-12 HR HR20010038A patent/HRP20010038A2/hr not_active Application Discontinuation
- 2001-07-10 HK HK01104767A patent/HK1035716A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EE200100010A (et) | Kinoliini derivaadid, nende kasutamine ravimina, neid sisaldavad farmatseutilised kompositsioonid ning ühendite ja farmatseutiliste kompositsioonide kasutamine patoloogilisest põletikust ja autoimmuunsusest tingitud haiguste ravis | |
EE200100007A (et) | Kinoliini derivaadid, nende kasutamine ravimina, neid sisaldavad farmatseutilised kompositsioonid ning ühendite ja farmatseutiliste kompositsioonide kasutamine patoloogilisest põletikust ja autoimmuunsusest tingitud haiguste ravis | |
EE04965B1 (et) | Imidasoimidasoolid ja triasoolid kui p?letikuvastased hendid, nende kasutamine ravimite valmistamiseks ning farmatseutiline kompositsioon | |
EE05170B1 (et) | Asabitskloalkaanid kui CCR5 modulaatorid, neid sisaldavad farmatseutilised kompositsioonid ja kombinatsioonid ning nende meditsiiniline kasutamine | |
EE04463B1 (et) | 3-arüülpropaanhappe derivaadid ja nende analoogid, nende valmistamise meetod, neid sisaldavad ravimkoostised ja ühendid kasutamiseks ravis | |
EE04354B1 (et) | Indolüül-3-glüoksüülhappe derivaadid, nende kasutamine ravimite valmistamiseks ja neid sisaldavad kasvajavastase toimega ravimid | |
EE200100446A (et) | Uued tritsüklilised ühendid ja nende kasutamine meditsiinis: nende valmistamismeetod ja neid sisaldavad farmatseutilised kompositsioonid | |
EE04275B1 (et) | Kinoliini derivaadid, nende valmistamismeetodid, kasutamine ja farmatseutilised kompositsioonid | |
EE04799B1 (et) | Ühendid, mis on kasulikud põletikuvastaste vahenditena, nende ühendite valmistamise meetodid ja neid sisaldavad farmatseutilised kompositsioonid | |
EE200100495A (et) | Sahhariidijääkidega asendatud 1,4-bensotiasepiin-1,1-dioksiidi derivaadid, meetod nende valmistamiseks, ühendite kasutamine ning neid sisaldav ravim | |
EE200200065A (et) | 3-aminopürasooli derivaadid, nende valmistamine ja kasutamine vähivastaste toimeainetena ning neid sisaldav farmatseutiline kompositsioon | |
IL147217A0 (en) | New spirooxindole derivatives and pharmaceutical compositions containing the same for treatment of pain | |
EE04399B1 (et) | Spiroasabitsüklilised heterotsüklilised ühendid, nende valmistamise protsess, neid sisaldavad ravimkoostised ja nende kasutamine ravis | |
EE200200357A (et) | Ravimaine suurenenud kontsentratsioone andvad farmatseutilised kompositsioonid | |
EE200300046A (et) | Asabitsüklilised ühendid, nende valmistamine ja kasutamine ravimitena ning neid sisaldav farmatseutiline kompositsioon | |
HUP0204143A3 (en) | Tricyclic 1-benzylpyrazole-3-carboxylic acid derivatives, preparation of the compounds, their use and pharmaceutical compositions containing them | |
HUP0002517A3 (en) | Derivatives of acyl-piperazinil-pyrimidins, preparation thereof, pharmaceutical compositions containing them and their use as medicaments | |
FI990171A (fi) | Uusia yhdisteitä ja koostumuksia tryptaasiaktiivisuuden liittyvien tautien hoitamiseksi | |
EE9500059A (et) | Asendatud 4-fenüül-6-aminonikotiinhappe derivaatide kasutamine ravimitena | |
EE200200075A (et) | Peroraalselt ja paikselt manustatavad farmatseutilised kompositsioonid | |
EE04493B1 (et) | Tsüklopenteeni derivaadid, neid sisaldav farmatseutiline kompositsioon ning ühendite kasutamine ravimina inimestel esinevate motiliini retseptoriga seotud häirete raviks | |
DE69713300T2 (de) | Benzopyran derivate mit leukotrien-antagonistischer wirkung | |
NO20021898L (no) | Farmasoytisk sammensetning inneholdende ciclesonid for applikasjon til mukosa | |
HUP0203884A3 (en) | Crystals of an oxyiminoalkanoic acid derivative and their use as antidiabetics and pharmaceutical compositions containing them | |
EE200200292A (et) | Asendatud norbornüülaminoderivaadid, nende valmistamine ja kasutamine ravimitena või diagnostilisteainetena ning neid sisaldav ravim |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
KB4A | Valid patent at the end of a year |
Effective date: 20041231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20051231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20061231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20071231 |
|
MM4A | Lapsed by not paying the annual fees |
Effective date: 20070714 |